amarin corporation

In a recent report, Jefferies has raised the price target on Amarin (NASDAQ: AMRN) from $21.00 to $25.00 after a AMR101 patent discussion with the FDA. In the report, Jefferies said, "We believe a longer-than-expected Hatch-Waxman patent extension of 5 years (vs. company guidance of 2 years)...

Jefferies & Company has raised the price target on Amarin Corporation (NASDAQ: AMRN) from $21 to $25 and maintains its Buy rating.

Hapoalim Securities has reported that Amarin Corporation's (NASDAQ: AMRN) 12 week Marine trial was positive. According to the report, “Amarin plans to submit an NDA for AMR101 to the FDA in 3Q11 for the indication studied in the MARINE trial (very high triglycerides) regardless of the outcome from...

Jefferies & Company has initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and $12 price target.

Jefferies & Company has initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and $12 price target.